The Society of Interventional Radiology (SIR) 2017 annual meeting will be held in Washington, D.C. At the meeting, experts will present information about interventional oncology and peripheral vascular, venous and neurovascular disease. Join ABK Biomedical as they present their studies entitled "Multi-modal "imageable" embolic microspheres: A preliminary study on occlusion effectiveness, level of occlusion and arterial distribution in a swine liver model” at the Walter E. Washington Convention Centre during the scientific session in Room 143C on March 5th from 3.00PM to 4.30PM. See http://www.sirmeeting.org for more details.
ABKs CEO Dr. Bob Abraham, spoke with Interventional Oncology 360 at the 2016 Annual Scientific Meeting of the Society of Interventional Radiology about our study of imageable embolic microspheres (IEMs) in a swine renal artery embolization model.
Read the full story here.
SIR2016 - 41st Annual Scientific Society of Interventional Radiology Meeting April 2 - 7, Vancouver, British Columbia, Canada
No other meeting offers the diversity of topics, the range of learning environments, the unparalleled access to expert faculty and leading thinkers in the specialty. Join ABK Biomedical on April 5th from 3.00PM to 4.30PM as they present their scientific abstract "A Bilateral Partial Swine Renal Artery Embolization Study using “Imageable” Embolic Microspheres: Assessment of Mechanism of Occlusion, Embolization Effectiveness, Device Migration and Safety” at the Vancouver Convention Centre during the scientific session. See http://www.sirmeeting.org for more details.
CIRSE2015 - 30th Annual Interventional Radiology Congress September 26 - 30, Lisbon, Portugal
For CIRSE 2015, the programme has been designed around six main themes, including, vascular Interventions, transcatheter embolisation, interventional oncology, neurointerventions, non-vascular interventions and IR management. Join ABK on Monday, September 28th, as they present a featured paper at the Centro de Congressos de Lisboa.
See http://www.cirse.org for more details.
SIR2015 - 40th Annual Scientific Society of Interventional Radiology Meeting February 28 - March 5, Atlanta, Georgia, US
The excitement and promise of IR are in the spotlight at SIR 2015. SIR's Annual Scientific Meeting is the world’s largest and most comprehensive IR educational experience designed for all professional levels and all practice environments. http://www.sirmeeting.org
Dynamic Halifax startup ABK Biomedical has engaged Enginuity to deliver engineering support for their ancillary delivery device for OccluRad. ABK are pioneering the use of radio-opaque embolic microspheres in the targeted treatment of tumors. Following early design in Ireland, ABK have brought core engineering to Halifax, in order to advance the device to production.
“Having access to unique creative engineering on our doorstep is key to meeting our investor expectations and delivering on our key business milestones” says Daniel Boyd, Chief Scientific Officer at ABK, adding “proximity is critical to rapid iteration, that’s what ABK needs as we move to the next phase.”
Enginuity are working on refining the device for use in OccluRad embolization microsphere preclinical trials, scheduled in early 2015. Enginuity will also undertake additional development and refinement on the ancillary delivery device for the first round of human testing, preparing for a full commercial launch for the product.
“We’re working hard to get the relevant regulatory approvals in place for Enginuity to provide value to ABK and the many other med tech players blossoming in the Maritimes” adds Ben Garvey, CEO of Enginuity Inc, based on Herring Cove Road in Halifax.
Dr Bob Abraham, ABK’s Chief Executive Officer sees the relationship as key to the successful launch of OccluRad embolization microspheres, adding “Enginuity have the right mix of skills, concise processes and personality to make the difference moving forwards.”
HALIFAX, Canada; October 15, 2014 - ABK Biomedical Inc., announced today the appointment of three leading experts in interventional radiology to its Clinical Advisory Board: Dr. Scott Goodwin, Dr. Jim Spies and Dr. Bob Lewandowski.
"We are thrilled to have these pioneers in uterine fibroid embolization and interventional oncology on our team of clinical advisors," said Dr. Bob Abraham, chief executive officer of ABK Biomedical. “The experience of these world leaders is going to be invaluable as we move OccluRad embolization microspheres into clinical trials and continue to expand our pipeline of novel radiopaque embolic therapies.”
Dr. Scott Goodwin, incoming Chair of ABK Biomedical’s clinical advisory board stated, “Minimally invasive, image-guided embolic therapies are becoming the patient's first choice for treatment of their uterine fibroids. ABK Biomedical’s innovations in this area makes this a very exciting opportunity to guide their efforts, together with the expertise of Dr. Spies and Dr. Lewandowski.”
Dr. Goodwin is an interventional radiologist, best known for introducing uterine artery embolization for the treatment of uterine fibroids (UAE) in North America. He is Chief of Radiology at UC Irvine Medical Center and also performs chemoembolization for liver cancer. Dr. Goodwin is the Hasso Brothers Chair of the Department of Radiological Sciences at University of California, Irvine Medical School. He has repeatedly been listed among the nation's Best Doctors in America® for Radiology, and is regarded as one of the top 10 researchers in uterine fibroids. Dr. Goodwin completed his M.D. at Harvard University, internship at Washington University, followed by his residency and fellowship at UCLA.
Dr. Jim Spies leads the Georgetown Uterine Fibroid Embolization Program, one of the largest and most experienced in the United States. Dr. Spies has been a principal investigator in five funded research trials, including the FIBROID Registry, a study of 3,000 women. He is Chair of the Radiology Department at MedStar Georgetown University hospital, Professor of Radiology at Georgetown University Medical Center and has published extensively on uterine artery embolization. He completed his M.D. at Georgetown University, residency at University of California, San Francisco, and fellowship in interventional radiology at New York University.
Dr. Bob Lewandowski is an Associate Professor of Radiology and Director of Interventional Oncology at the Northwestern University Feinberg School of Medicine in Chicago. He has published extensively on chemoembolization and radioembolization to treat liver cancer and is a world authority in interventional radio-oncology. A leading researcher, Dr. Lewandowski is involved with both pre-clinical and clinical studies in Interventional Oncology. Dr. Lewandowski received his M.D. from Michigan State University, completed residency at William Beaumont Hospital and his fellowship at Northwestern Hospital.
ABK Biomedical Inc. is pursuing validation, production and sale of OccluRad embolization microspheres, ABK's lead radiopaque embolic product, as it develops additional therapies for chemoembolization and radioembolization. While still investigational, ABK’s innovative radiopaque embolic therapies have the potential to provide simpler, safer and more cost effective solutions for treating hypervascular tumors and diseases.
HALIFAX, Canada; October 2, 2014 – ABK Biomedical Inc.,announced today it is consolidating its operations to Halifax. Heading up this consolidation will be ABK Biomedical’s new Chief Executive Officer, Dr. Bob Abraham. As an ABK Biomedical co-founder, Dr. Abraham also serves as Chief Medical Officer and is a member of its Board of Directors.
The company focus to Halifax and CEO appointment follow ABK Biomedical’s recent award of $2.14M from Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). The AIF award will enable ABK to simplify and enhance chemotherapy and radiotherapy for cancer patients with ABK’s novel radiopaque embolic beads. In addition to ACOA’s support, ABK has received funding through strong local, national and US based angel and institutional investment. The commitment of the private investors, with the leverage from AIF funding will fuel ABK’s lead product first-in-human trials as well as advancing a robust pipeline of products.
In his new CEO role, Dr. Abraham will steer ABK’s lead product OccluSystem through clinical validation, regulatory approval and market readiness. Dr. Abraham will also lead the expansion of the company’s product pipeline as ABK Biomedical looks to develop next generation resorbable, radiopaque, drug eluting and radioembolic agents to be used for chemoembolization and radioembolization treatment of liver cancer.
“As a nationally recognized embolization expert, we are delighted to have Dr. Abraham as our new, full-time CEO,” said Dr. Aaron Berez, chairman of the board of ABK Biomedical. “His experience as a clinician, entrepreneur and med tech investor as well as his dedication to patients and passion for innovation make him the ideal candidate to lead ABK Biomedical.”
“Having the full ABK Biomedical team, including product engineering, quality management system (QMS), regulatory, and R&D, together in our Halifax facilities supports our commitment to bringing our novel embolic systems to patients as quickly as possible,” said CEO Dr. Bob Abraham.
Dr. Abraham has spent more than 20 years as a practicing clinician and interventional radiologist at Capital Health (CDHA). He has successfully licensed catheter innovations and established the Uterine Fibroid Embolization (UFE) program at QEII Health Sciences Centre and IWK in 2001. Dr. Abraham earned his medical degree from Dalhousie University in Halifax, interned at St. Paul’s Hospital in Vancouver, returned to complete specialty training in Diagnostic Imaging at Dalhousie University and then completed subspecialty training in Interventional Radiology at the Royal Melbourne Hospital in Australia. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) and just completed his tenure as Chair for the Royal College's exam in Diagnostic Radiology. He is currently President-Elect for the Canadian Association of Radiologists (CIRA) and will assume the role of President in June 2015.
Founded in 2012, ABK Biomedical Inc. is pursuing development, production and sale of embolic agents and peripheral vascular delivery devices. The company’s radiopaque OccluSystem and pipeline products, while still investigational, have the potential to provide simpler, safer and more cost effective solutions for treating hypervascular tumors and diseases.
HALIFAX, Canada; July 9, 2014 – ABK Biomedical Inc., a medical device company, will receive $2.14 Million from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). Using ABK Biomedical’s novel embolic microspheres, this funding will enable the company to simplify and enhance chemotherapy and radiotherapy for cancer patients.
"ACOA’s recognition of the potential of our beads to improve embolization and treat tumours is a tremendous boost to ABK,” commented Dr. Daniel Boyd, Chief Scientific Officer at ABK Biomedical.
"This funding will enable us to take our lead product into clinical trials in Nova Scotia and help us move forward two new therapies targeting liver cancers. All these products have the potential to improve cancer treatment right here in Nova Scotia,” remarked Dr. Bob Abraham, Chief Medical Officer at ABK Biomedical.
ABK Biomedical’s OccluRad embolization microspheres are radiopaque. This makes them clearly visible under X-ray and reduces the use of potentially toxic X-ray dye required with other embolic therapies. The combination of ABK’s radiopaque microspheres and its accompanying delivery device makes the device safer, more accurate, and effective for embolotherapy.
With the global market for minimally invasive surgeries reaching $50 billion US by 2019[i], ABK Biomedical’s OcculRad embolization microspheres is well placed to address minimally invasive approaches to uterine fibroid treatment, liver cancer and many other clinical applications. Under the AIF program, ABK will prepare the next generation of its proprietary embolic platform for these clinical applications.
[i] Minimally invasive surgery market is expected to reach USD 50.60 billion globally in 2019: Transparency Market Research. (2014, January 6).
CIRSE 2014 - 30th Annual Cardiovascular Interventional Radiology Society in Europe Congress September 13 - 17, Glasgow, UK
The CIRSE Annual Congress has become the leading European platform for interventionists, featuring more than 250 hours of sessions, workshops and symposia. CIRSE offers its over 6,500 participants the ideal opportunity to increase their knowledge on image-guided minimally invasive procedures and to present their latest research findings.